Early-stage potential Onkaido Therapeutics is a small biotechnology company (11-50 employees) with modest current revenue, indicating potential for strategic partnerships or collaborations to accelerate pipeline development and bring in early-stage funding or co-development opportunities.

Madrid focus Headquartered in Madrid, Spain, the company represents an opportunity to partner with regional life sciences hubs, access European funding programs, and leverage local manufacturing or R&D contracts to support clinical and preclinical programs.

Technology partnerships Without explicit technology details, target outreach to CROs, contract development and manufacturing organizations, and specialized biotech suppliers that serve small biotech firms to provision lab services, analytical testing, and early-stage manufacturing.

Comparable size fit With peers in the 10-50 employee range and revenue under $1M-$10M, Onkaido may be seeking cost-effective, scalable solutions. Focus on affordable, modular tools, SaaS platforms, and services that align with lean operations and staged financing.

Growth enablers Position offerings around accelerate-to-clinic services, including grant navigation, regulatory consulting, IP strategy support, and strategic partnering to attract co-development funds and late-stage investors as the company scales.